Skip to main content
AMGN
NASDAQ Life Sciences

Amgen Drops 5% as Novartis Trial Failure Clouds Olpasiran Outlook

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$415.26
Mkt Cap
$236.381B
52W Low
$269.77
52W High
$447.03
52W Position info
54% above low
Off High info
7.1% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

AMGN sits 54% above its 52-week low of $269.77.

Summary

Amgen shares fell 5.2% premarket after Novartis's cardiovascular drug pelacarsen failed its phase 3 trial, raising doubts about Amgen's similar drug olpasiran, which has phase 3 data expected in mid-2028. Cantor analyst Carter Gould noted the market had priced in a 65%+ probability of success for olpasiran, so the setback hit sentiment hard. BMO Capital also downgraded Amgen to Market Perform from Outperform, though it kept a $450 price target. The drop reflects a repricing of pipeline risk rather than any company-specific news. Watch for any Amgen commentary on olpasiran's development timeline or additional analyst revisions.

At the time of this announcement, AMGN was trading at $415.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $236.4B. The 52-week trading range was $269.77 to $447.03. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

AMGN - Latest Insights

AMGN
Nov 05, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $477.40
Real-time Price: $447.59 info
Change: -$29.81 (-6%) info
Market Cap: $242.469B info
AMGN
Nov 03, 2026, 6:37 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $464.92
Real-time Price: $447.59 info
Change: -$17.33 (-4%) info
Market Cap: $242.469B info
AMGN
Nov 03, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $463.00
Real-time Price: $447.59 info
Change: -$15.41 (-3%) info
Market Cap: $242.469B info
AMGN
Nov 03, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $460.57
Real-time Price: $447.59 info
Change: -$12.98 (-3%) info
Market Cap: $242.469B info
AMGN
Oct 26, 2026, 9:23 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $448.79
Real-time Price: $447.59 info
Change: -$1.20 (-0.27%) info
Market Cap: $242.469B info